Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
acknowledgement, adult, amantadine, antiviral, APACHE, appeal, arm, assembled, Assent, Bactrim, baloxavir, baseline, Bellina, bifurcation, biometric, blood, Blueprint, bOutcome, Brexit, caffeine, cessation, chose, clause, climate, CMS, complicating, conserved, cPrimary, crude, currency, customer, cutoff, cycle, DDI, death, deployment, destruction, detrimental, died, digoxin, Distinguishing, district, dollar, downturn, earliest, economy, EEA, efavirenz, EMA, embedded, endonuclease, engineering, entirety, epithelial, explanatory, extinguishment, flu, fluid, forward, Frank, fundraising, furlough, futility, GDPR, genetic, glabrata, ill, immunocompromised, incentivize, incidence, indeterminate, influenza, inhibitor, Inspector, instance, Interaction, interval, intrinsic, intrusion, Ireland, Jordan, Journal, Kingdom, leadership, leave, lethal, lieu, Likewise, line, malware, Matthew, McLinn, metformin, microbial, midazolam, misleading, missing, mobile, modality, mode, Mongiello, monoclonal, month, mount, moxifloxacin, multitude, neuraminidase, neurominidase, NIH, nominate, nonclinical, North, notification, notified, older, onset, oseltamivir, overcame, oversee, pandemic, par, paragraph, pari, passu, Peramivir, permission, pharmacy, phosphate, PI, pitavastatin, placebo, plasma, pocket, poorly, Populationa, posture, PR, predominantly, preempted, pregnant, pro, prompted, prone, pseudonymised, QIPD, QRS, QT, radiological, rata, recipient, referendum, Relenza, repaglinide, replication, respiratory, ReSTORE, retention, rimantadine, robust, rosuvastatin, Royal, Score, season, seasonal, secondary, settle, shut, social, sophistication, stable, strict, subscription, symptom, Tamiflu, television, thereunder, timeline, transport, Trickett, true, truthful, turnover, unconstitutional, unqualified, vaccine, verify, weak, week, weigh, Wendler, whichever, Wholesale, winding, worthy, Xofluza, Xolfluza, Young
Removed:
authoritative, balanced, checking, commenced, Composite, compromise, conjunction, deposit, easily, enabled, exceeded, forecast, generation, graph, greatest, guaranteed, headcount, Index, inspect, Latin, mature, maximizing, membrane, minimize, NBI, overuse, presence, revolutionize, sensitivity, subsidiary, suffice
Filing tables
Filing exhibits
- 10-K Annual report
- 21.1 List of Subsidiaries
- 23.1 Consent of Independent Public Accounting Firm
- 31.1 Certification of CEO Pursuant to Securities Exchange Act of 1934
- 31.2 Certification of CFO Pursuant to Securities Exchange Act of 1934
- 32.1 Certification of CEO Pursuant to Sarbanes-oxley Act of 2002
- 32.2 Certification of CFO Pursuant to Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
Related press release
CDTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 Nos. 333-211472, 333-221535, 333-225061, 333-225445, 333-225787, and 333-228268) of Cidara Therapeutics, Inc., and |
| (2) | Registration Statements (Form S-8 Nos. 333-216722, 333-203434, 333-210263, and 333-228282) pertaining to the 2013 Stock Option and Grant Plan, the 2015 Equity Incentive Plan, and the 2015 Employee Stock Purchase Plan of Cidara Therapeutics, Inc.; |
of our report dated February 28, 2019, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cidara Therapeutics, Inc. for the year ended December 31, 2018.
/s/ Ernst & Young LLP
San Diego, California
February 28, 2019